Why no Allergan product? I think Allergan was really working at high pressure on a launch. But then Sirona published the following sentence about the Gycoprotemim study:
"TFC-1326 could be a stand-alone product for anti-aging or an adjunctive option to Botox® and dermal filler treatments depending on consumer goals."
So it has the potential to complement or REPLACE Botox and Juvederm. Sirona probably wanted to force a deal with Allergan with this sentence, but it didn't come to that. The negotiations probably broke off at the end of last year because Howie didn't want to accept another deal with bad conditions. Now Allergan sees its annual 4 billion net revenue with Juvederm and cosmetical Botox in danger. If Allergan can't buy/license the drug, they can at least try to bleed Sirona dry, knowing full well what Sirona's financial situation is.
What do you think?